Rhenman & Partners Asset Management’s NeuroDerm Ltd. Ordinary Shares NDRM Stock Holding History

Rhenman & Partners Asset Management’s Portfolio NDRM Stock Details NDRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-461,654	Closed	-$13.8M	–	120
2017 Q2	$13.8M	Buy	+461,654	New	+$12M	1.98%	16
2017 Q1	–	Sell	-142,546	Closed	-$3.17M	–	113
2016 Q4	$3.17M	Sell	142,546 -2,000	-1%	-$37.4K	0.61%	61
2016 Q3	$2.67M	Hold	144,546	–	–	0.42%	71
2016 Q2	$2.35M	Buy	+144,546	New	+$2.43M	0.42%	69

Other funds holding NDRM

AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

SAM

Sandell Asset Management New York $179M AUM 65.55% 1-Year Est. Return

Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $203M AUM 34.78% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return

CFIC

City Financial Investment Company London, United Kingdom $562M AUM 5.93% 1-Year Est. Return

WIC

Water Island Capital New York $1.08B AUM 105.75% 1-Year Est. Return

FTCM

First Trust Capital Management Chicago, Illinois $1.72B AUM 70.66% 1-Year Est. Return

Rhenman & Partners Asset Management's NDRM Position: Q3 2017 in Review

Rhenman & Partners Asset Management sold out of NeuroDerm Ltd. Ordinary Shares (NDRM) in Q3 2017, closing a stake of 461,654 shares — an estimated $13.8M sold.

Rhenman & Partners Asset Management first reported a position in NDRM in Q2 2016 and held it in 4 quarters. The position peaked at $13.8M in Q2 2017. 81 funds tracked by Wall St. Rank hold NDRM as of Q3 2017.

Rhenman & Partners Asset Management reported no remaining NeuroDerm Ltd. Ordinary Shares position as of Q3 2017 after selling out during the quarter.
Rhenman & Partners Asset Management sold 461,654 NeuroDerm Ltd. Ordinary Shares shares in Q3 2017, an estimated $13.8M.
Rhenman & Partners Asset Management first reported a position in NeuroDerm Ltd. Ordinary Shares in Q2 2016 and held it in 4 quarters.
Rhenman & Partners Asset Management's NeuroDerm Ltd. Ordinary Shares position peaked at $13.8M in Q2 2017.
81 funds tracked by Wall St. Rank held NeuroDerm Ltd. Ordinary Shares as of Q3 2017.

Based on Rhenman & Partners Asset Management's 13F filing for Q3 2017, filed 13 Oct 2017.